Photodynamic therapy in urology: What can we do now and where are we heading?

被引:49
作者
Bozzini, G. [1 ,2 ,3 ]
Colin, P. [1 ,2 ,3 ]
Betrouni, N. [2 ,3 ]
Nevoux, P. [1 ]
Ouzzane, A. [1 ]
Puech, P. [4 ]
Villers, A. [1 ]
Mordon, S. [2 ,3 ]
机构
[1] Ctr Hosp Reg Univ Lille, Dept Urol, Lille, France
[2] INSERM, U703, F-59120 Loos, France
[3] Univ Lille Nord France, CHU Lille, F-59000 Lille, France
[4] Ctr Hosp Reg Univ Lille, Dept Radiol, Lille, France
关键词
Photodynamic therapy; Prostate cancer; Penile cancer; Urothelial cancer; Kidney cancer; Testicular cancer; TRANSITIONAL-CELL CARCINOMA; SUPERFICIAL BLADDER-CANCER; RECURRENT PROSTATE-CANCER; EARLY CLINICAL-EXPERIENCE; 5-AMINOLEVULINIC ACID; IN-VIVO; METHYL-AMINOLEVULINATE; OPTICAL-PROPERTIES; LIGHT DELIVERY; DIAGNOSIS;
D O I
10.1016/j.pdpdt.2012.01.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Photodynamic therapy (PDT) is an innovative technique in oncologic urology. Its application appears increasingly realistic to all kind of cancers with technological progress made in treatment planning and light delivery associated with the emergence of novel photosensitizers. The aim of this study is to review applications of this technique in urology. Materials and methods: We reviewed the literature on PDT for urological malignancies with the following key words: photodynamic therapy, prostate cancer, kidney cancer, urothelial cancer, penile cancer and then by cross-referencing from previously identified studies. Results: Focal therapy of prostate cancer is an application of PDT. Clinical studies are ongoing to determine PDT efficacy and safety. PDT as salvage treatment after radiotherapy has been tested. Oncologic results were promising but important side effects were reported. Individual dosimetric planning is necessary to avoid toxicity. PDT was tested to treat superficial bladder carcinoma with promising oncologic results. Serious side effects have limited use of first photosensitizers generation. Second generation of photosensitizer allowed reducing morbidity. For upper urinary tract carcinoma and urethra, data are limited. Few studies described PDT application in penile oncology for conservative management of carcinoma in situ and premalignant lesions. For renal cancer, PDT was only tested on preclinical model despite of its potential application. No data is available concerning PDT application for testicular cancer. Conclusion: PDT clinical applications in urology have proved a kind of efficiency balanced with an important morbidity. Development of new photosensitizer generations and improvement in illumination protocols should permit to decrease side effects. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:261 / 273
页数:13
相关论文
共 85 条
[1]  
Alexsandr A, 2010, 8 PHTOD THER PHOT CL
[2]   Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate [J].
Angell-Petersen, Even ;
Sorensen, Roar ;
Warloe, Trond ;
Soler, Ana Maria ;
Moan, Johan ;
Peng, Qian ;
Giercksky, Karl-Erik .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (02) :265-271
[3]  
Arumainayagam NMC, 2010, EAU ANN M
[4]   The place of photodynamic therapy in gynecology [J].
Ascencio, M. ;
Collinet, P. ;
Cosson, M. ;
Vinatier, D. ;
Mordon, S. .
GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2007, 35 (11) :1155-1165
[5]   Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy [J].
Ascencio, Manuel ;
Collinet, Pierre ;
Farine, M. O. ;
Mordon, Serge .
LASERS IN SURGERY AND MEDICINE, 2008, 40 (05) :332-341
[6]  
AUA, 2007, GUID MAN CLIN LOC PR
[7]   Photodynamic therapy with methyl aminolevulinate for atypia/carcinoma in situ of the penis [J].
Axcrona, Karol ;
Brennhovd, Bjorn ;
Alfsen, Glenny Cecilie ;
Giercksky, Karl-Erik ;
Warloe, Trond .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2007, 41 (06) :507-510
[8]  
Azzouzi A-R, 2011, AUA 2011 WASH DC
[9]  
Babilas P, 2010, GIORN ITAL DERMAT V, V145, P613
[10]   Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study [J].
Berger, AP ;
Steiner, H ;
Stenzl, A ;
Akkad, T ;
Bartsch, G ;
Holtl, L .
UROLOGY, 2003, 61 (02) :338-341